



Charité Research  
Organisation



Comprehensive Cancer Center  
Universitätstumorzentrum

## FTIH-POC HAEMATOTOLOGY-ONCOLOGY



Charité Research Organisation (CRO) and Charité Comprehensive Cancer Center (CCCC) jointly provide a dedicated Phase I platform offering a complete solution for the design and conduct of early phase haematology-oncology studies in the FTIH-POC space. The platform combines the experience of leading haematologists and oncologists with FTIH-POC expertise and capabilities. Traditionally, early phase oncology studies have run in clinics along with late phase studies. While such a set-up provides access to the necessary clinical expertise, it often lacks access to the dedicated resources needed for complex early phase studies. The Phase I platform offered by CRO and CCCC provides exactly this. The result is an early phase haematology-oncology capability, supported by the huge clinical expertise and patient resources of the Charité, located within a thriving academic setting and with fast and effective contracting of all services.

**Charité Research  
Organisation GmbH**

Charitéplatz 1  
10117 Berlin, Germany

Tel. +49 (0)30 450 539 200  
Fax +49 (0)30 450 539 900

[enquiries@charite-research.org](mailto:enquiries@charite-research.org)  
[www.charite-research.org](http://www.charite-research.org)

# CAPABILITIES AND RESOURCES

## SERVICES

FTIH-POC Oncology Facility  
Dedicated Staffing  
Consultancy

## BIOMARKERS

German Reference Lab for Immunophenotyping  
Bone Marrow Morphology  
Experimental Biomarkers

## IMAGING

CT Scans  
PET Scans  
MRI

## HAEMATOLOGY-ONCOLOGY Charité – Universitätsmedizin Berlin Partners with Expertise & International Standing

The integral relationship with CCCC provides access to outstanding clinical expertise and experience across a wide range of indications and therapeutic approaches. Crucially, with over 10,000 patients seen per year, the collaboration assures excellent enrolment performance.



**Prof. Dr. med. Antonio Pezzutto**

Medical Director, Charité Department for Haematology-Oncology and Tumor Immunology (Charité Campus Benjamin Franklin)

Board certified in haematology (University of Padova), internal medicine and rheumatology (University of Heidelberg), he is a faculty member of the Charité with an extensive background in clinical and translational medicine. As leader of the molecular immunotherapy group at the Max Delbrück Center for Molecular Medicine, Prof. Pezzutto has been involved in the development of gene therapy and the conduct of immunotherapy studies - including First Time in Human and other Phase I studies. Prof. Pezzutto has long standing experience as a Principal Investigator for international clinical trials in Phases I to III, across a wide variety of indications. His main focus is on the treatment of malignant lymphomas, leukemias and multiple myeloma.



**Prof. Dr. med. Ulrich Keilholz**

Medical Director, Charité Department for Haematology-Oncology (Charité Campus Benjamin Franklin), Deputy Director, Charité Comprehensive Cancer Center

Prof. Keilholz previously served as head of the tumour immunology group in Heidelberg where he also became board certified in internal medicine and haematology-oncology. He is active in the European Organisation for Research and Treatment of Cancer (EORTC). Prof. Keilholz has also been elected as National Representative for Germany of the European Society for Medical Oncology (ESMO). Furthermore, in addition to his other duties, Prof. Keilholz chairs the unit for interdisciplinary medical tumour therapy at the Charité.

## ABOUT US

Charité Research Organisation is a daughter company of Charité - Universitätsmedizin Berlin. Since 2006 it has been a pioneer in the FTIH - POC space, supporting a translational approach to early clinical research with direct into patient studies across a wide range of indication areas. While part of the Charité family, CRO is an independent organisation which contracts studies directly with the pharmaceutical and biopharmaceutical industries. CRO counts the majority of the top 20 companies amongst its clients.

Charité Comprehensive Cancer Center oversees the clinical operations of all departments within the Charité that are caring for tumour patients. The clinical spectrum covers all tumour types and draws from the approximately seven million population of Berlin, Brandenburg and beyond. Clinical expertise is coupled with modern facilities for imaging and molecular diagnostics.

## Selected Key Indication Areas:

Acute and Chronic Leukaemia
Primary CNS Lymphoma
Myelodysplasia
Multiple Myeloma
Malignant Lymphomas
Melanoma
Head-and-Neck Cancer
Lung Cancer
Colorectal Cancer
Breast Cancer
Renal Cancer
Solid Tumours of other Internal Organs
Specific Rare Cancers